LeukoSite is pursuing what it calls an "integrated approach" to understanding the biology of leukocyte recruitment--a key mechanism in inflammation and auto-immunity-- to find inhibitors of the process on a disease-specific basis.
You may also be interested in...
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.
A new document from the US FDA details acceptable substitutions for COVID-19 testing components that may be difficult to come by. See what the regulatory agency said about it here.